Overview Financials News + Filings Key Docs Ownership Insiders
|
In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, general and administrative [+] | 0.1 | 0.4 | 0.4 | 0.5 | 0.5 | 0.9 | 0.9 | 0.0 |
General and administrative | 0.1 | 0.4 | 0.4 | 0.5 | 0.5 | 0.9 | 0.9 | 0.0 |
EBIT [+] | -0.1 | -0.4 | -0.4 | -0.5 | -0.5 | -0.9 | -0.9 | 0.0 |
EBIT growth | -68.0% | -12.5% | -59.4% | 1381.8% | -64.2% | | | |
Interest income | 0.2 | 0.0 | 2.6 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 |
Interest income | 0.2 | 0.0 | 2.6 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 |
Other income (expense), net [+] | | -1.3 | 3.5 | 3.8 | 10.6 | -0.2 | 1.3 | 10.9 |
Change in fair value of warrants | | -1.3 | 3.5 | 3.8 | 10.6 | -0.2 | 1.3 | 10.9 |
Other | 0.2 | -1.2 | 6.1 | 4.6 | 10.6 | -0.2 | 1.3 | 10.9 |
Pre-tax income | 0.0 | -1.6 | 5.8 | 4.1 | 10.2 | -1.1 | 0.3 | 10.9 |
Income taxes | 0.0 | 0.0 | 0.3 | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
Tax rate | 0.0% | 0.0% | 5.0% | | 0.0% | 0.0% | 0.0% | 0.0% |
Net income | 0.0 | -1.6 | 5.5 | 4.3 | 10.2 | -1.1 | 0.3 | 10.9 |
|
Basic EPS [+] | $0.00 | ($0.12) | $0.09 | $0.07 | $0.16 | ($0.02) | $0.01 | $0.17 |
Growth | -98.9% | -172.7% | 1602.7% | -60.4% | -1166.8% | | | |
Diluted EPS [+] | $0.00 | ($0.12) | $0.09 | $0.07 | $0.16 | ($0.02) | $0.01 | $0.17 |
Growth | -98.9% | -172.7% | 1602.7% | -60.4% | -1166.8% | | | |
|
Shares outstanding (basic) [+] | 13.9 | 13.9 | 62.5 | 62.5 | 62.5 | 62.5 | 62.5 | 62.5 |
Growth | -77.8% | -77.8% | 0.0% | 0.0% | 0.0% | | | |
Shares outstanding (diluted) [+] | 13.9 | 13.9 | 62.5 | 62.5 | 62.5 | 62.5 | 62.5 | 62.5 |
Growth | -77.8% | -77.8% | 0.0% | 0.0% | 0.0% | | | |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|